Copyright © 2021 Pharmascimed. All Rights Reserved.
Sales
- February 25, 2019
- 0
Novartis has acquired rights to TQJ230 from Akcea Therapeutics, a novel cardiovascular drug that could become first-in-class and has the potential to treat million of patients. TQJ230 is based on the...
Read more- February 25, 2019
- 0
Roche and Spark Therapeutics have announced they are to enter a definitive merger agreement for Roche to fully acquire Spark for $4.3bn - the first company to gain approval for...
Read more- February 14, 2019
- 0
With focus firmly fixed on the future, Johnson & Johnson have confirmed payment of $3.4bn for California-based Auris, a leader in the surgical robotics market. Auris Health is a privately...
Read more- February 7, 2019
- 0
Sales of Merck Sharp & Dohme's immuno-oncology drug Keytruda grew a massive 66% year-on-year bringing in $2.15bn in the fourth quarter surpassing most analysts expectations. Earlier in January MSD announced...
Read more- February 6, 2019
- 0
Britain's largest drugmaker GlaxoSmithKline has announced its 2018 financial results, showing that the company is making progress in rebuilding its pharmaceutical pipeline despite competition from generics. However the company has also...
Read more- February 5, 2019
- 0
GlaxoSmithKline has signed a wide-reaching deal worth up to £3.2bn with German pharma giant Merck KGaA for the rights to a new type of immunotherapy for various difficult-to-treat cancers. Both...
Read more- February 3, 2019
- 0
Novartis have announced a 5% in net sales in 2018, bringing the total to $51.9bn. Growth was primarily driven by Cosentyx (secukinumab), the human IgG1k monoclonal antibody for the treatment of...
Read more- February 1, 2019
- 0
Johnson & Johnson has joined the ranks of Novartis and Pfizer in gene therapy having been granted licenses for three eye disease programs from Meiragtx for $100m as well as...
Read more- January 30, 2019
- 0
UK biotech managed to attract a record-breaking £2.2bn in investment last year according to a BioIndustry Association (BIA) report. The news essentially means that British firms were able to capture...
Read more- January 29, 2019
- 0
London-based Smart Respiratory Products has developed a device for asthma sufferers that detects exacerbations before patients feel them. The company began work in 2016 in the aim to revolutionise asthma...
Read more